Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Confirms Retirement of Co-Founder Dr. Ronan Lambe


a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries, today confirmed, that Dr. Ronan Lambe retired as a
non-executive director at the Annual General Meeting (AGM) of the
Company on the 24th July 2018. This follows the announcement
in the 2018 AGM Notice, dated 12th June 2018, that Dr. Lambe
had decided to retire and not seek re-election at the AGM.

CEO Dr. Steve Cutler commented, "I would like to recognize the
immense contribution of Dr. Ronan Lambe, ICON's co-founder with Dr. John
Climax, who after 28 years of service, has retired from our Board. We
thank Ronan for the hugely positive influence he has had on shaping ICON
into the industry leader it is today, and we wish him well in his

This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 93 locations in 37 countries and
has approximately 13,650 employees. Further information is available at

Source: ICON plc

All at ICON.


View Comments and Join the Discussion!